Zobrazeno 1 - 10 of 22 pro vyhledávání: '"Matthew E. Stokes"'
1
Akademický článek
Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation
Autor: Matthew E. Stokes, Kerstin Wenzl, C. Chris Huang, María Ortiz, Chih-Chao Hsu, Matthew J. Maurer, Nicholas Stong, Yumi Nakayama, Lei Wu, Hsiling Chiu, Ann Polonskaia, Samuel A. Danziger, Fadi Towfic, Joel Parker, Rebecca L. King, Brian K. Link, Susan L. Slager, Vivekananda Sarangi, Yan W. Asmann, Joseph P. Novak, Akshay Sudhindra, Stephen M. Ansell, Thomas M. Habermann, Patrick R. Hagner, Grzegorz S. Nowakowski, James R. Cerhan, Anne J. Novak, Anita K. Gandhi
Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract Immunochemotherapy has been the mainstay of treatment for newly diagnosed diffuse large B-cell lymphoma (ndDLBCL) yet is inadequate for many patients. In this work, we perform unsupervised clustering on transcriptomic features from a large c
Externí odkaz: https://doaj.org/article/4dae5fe5634e4259b6d610f0ad207e8d
Zobrazit plný text záznamu
2
Akademický článek
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL
Autor: Kerstin Wenzl, Matthew E. Stokes, Joseph P. Novak, Allison M. Bock, Sana Khan, Melissa A. Hopper, Jordan E. Krull, Abigail R. Dropik, Janek S. Walker, Vivekananda Sarangi, Raphael Mwangi, Maria Ortiz, Nicholas Stong, C. Chris Huang, Matthew J. Maurer, Lisa Rimsza, Brian K. Link, Susan L. Slager, Yan Asmann, Patrizia Mondello, Ryan Morin, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Andrew L. Feldman, Rebecca L. King, Grzegorz Nowakowski, James R. Cerhan, Anita K. Gandhi, Anne J. Novak
Publikováno v: Blood Cancer Journal, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Recent genetic and molecular classification of DLBCL has advanced our knowledge of disease biology, yet were not designed to predict early events and guide anticipatory selection of novel therapies. To address this unmet need, we used an int
Externí odkaz: https://doaj.org/article/01ad00fd8b6b4753b3568b00e0172eef
Zobrazit plný text záznamu
3
Akademický článek
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
Autor: Keiji Kurata, Anna-James Bott, Mark A. Tye, Leona Yamamoto, Mehmet K. Samur, Yu-Tzu Tai, James Dunford, Catrine Johansson, Filiz Senbabaoglu, Martin Philpott, Charlotte Palmer, Karthik Ramasamy, Sarah Gooding, Mihaela Smilova, Giorgia Gaeta, Manman Guo, John C. Christianson, N. Connor Payne, Kritika Singh, Kubra Karagoz, Matthew E. Stokes, Maria Ortiz, Patrick Hagner, Anjan Thakurta, Adam Cribbs, Ralph Mazitschek, Teru Hideshima, Kenneth C. Anderson, Udo Oppermann
Publikováno v: Blood Cancer Journal, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Multiple myeloma (MM) is a plasma cell malignancy characterised by aberrant production of immunoglobulins requiring survival mechanisms to adapt to proteotoxic stress. We here show that glutamyl-prolyl-tRNA synthetase (GluProRS) inhibition c
Externí odkaz: https://doaj.org/article/9a68487f85794fbbb8d94c8c96041cdb
Zobrazit plný text záznamu
8
Akademický článek
Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus.
Autor: Kristen R Taylor Meadows, Marcos W Steinberg, Bryan Clemons, Matthew E Stokes, Gregory J Opiteck, Robert Peach, Fiona L Scott
Publikováno v: PLoS ONE, Vol 13, Iss 4, p e0193236 (2018)
Ozanimod (RPC1063) is a specific and potent small molecule modulator of the sphingosine 1-phosphate receptor 1 (S1PR1) and receptor 5 (S1PR5), which has shown therapeutic benefit in clinical trials of relapsing multiple sclerosis and ulcerative colit
Externí odkaz: https://doaj.org/article/1c84ef495f954c94be46c4f5a73a49ab
Zobrazit plný text záznamu
10
Large-scale Analyses of Disease Biomarkers and Apremilast Pharmacodynamic Effects
Autor: Matthew Trotter, Jing Ai, Peter H. Schafer, Matthew E. Stokes, Irina V. Medvedeva, Robert Yang, Dominic Eisinger, Samuel T. Labrie
Publikováno v: Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Scientific Reports
Finding biomarkers that provide shared link between disease severity, drug-induced pharmacodynamic effects and response status in human trials can provide number of values for patient benefits: elucidating current therapeutic mechanism-of-action, and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70b123684332a45ee029833dbc638275
http://link.springer.com/article/10.1038/s41598-020-57542-5
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje